Form 4: LeMaitre Vascular CEO George W. LeMaitre Sells Shares Under 10b5-1 Plan

George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, Inc., executed multiple sales of common stock between May 6 and May 8, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, Inc., reported the sale of common stock between May 6 and May 8, 2024.
• The sales were executed under a pre-arranged 10b5-1 trading plan adopted on June 2, 2023.
• On May 6, 2024, Mr. LeMaitre sold 23,206 shares at a weighted average price of $76.1211, 29,500 shares at $75.2308, and 16,200 shares at $75.9406.
• On May 7, 2024, he sold 26,044 shares at a weighted average price of $75.2389 and 20,256 shares at $75.856.
• On May 8, 2024, Mr. LeMaitre sold 8,000 shares at a weighted average price of $75.3034.
• Following these transactions, Mr. LeMaitre directly owns 2,079,128 shares of LeMaitre Vascular common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document reports routine stock sales under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they interpret the sales negatively, although the existence of a 10b5-1 plan mitigates this concern.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal, as these transactions do not directly affect the company's operations.

Key Dates